Foundation Medicine Files Registration Statement for Proposed Initial Public Offering of Common Stock

Foundation Medicine Files Registration Statement for Proposed Initial Public Offering of Common Stock

CAMBRIDGE, Mass., Jul 29, 2013 (BUSINESS WIRE) -- Foundation Medicine, Inc. today announced the filing of a Registration Statement on Form S-1 with the Securities and Exchange Commission for a proposed initial public offering of shares of its common stock. All of the shares to be sold in the proposed offering will be offered by Foundation Medicine. Foundation Medicine has applied for a listing of its common stock on The NASDAQ Stock Market under the symbol "FMI".

Goldman, Sachs & Co. and J.P. Morgan Securities, LLC will act as joint book-running managers of the offering. A copy of the preliminary prospectus relating to this offering may be obtained, when available, from: Goldman, Sachs & Co., Attention: Prospectus Department, 200 West Street, New York, NY 10282, or by telephone at (866) 471-2526, facsimile at (212) 902-9316, or e-mail at [email protected]; or J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

SOURCE: Foundation Medicine, Inc. Media - Foundation Medicine Dan Budwick Pure Communications, Inc. 973-271-6085 or Investors - Foundation Medicine Matt Clawson, 617-418-2283

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.

The RNAi therapy drove a 72% reduction in urinary oxalate from baseline, boosting Alnylam’s hopes of using the drug in a broad patient population.